Illumina/$ILMN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Ticker

$ILMN
Sector
Primary listing

Employees

9,000

Illumina Metrics

BasicAdvanced
$16B
12.91
$7.91
1.43
-

What the Analysts think about Illumina

Analyst ratings (Buy, Hold, Sell) for Illumina stock.

Bulls say / Bears say

Illumina’s forecast for 2025 revenue, between $4.28 billion and $4.40 billion, is below the Wall Street consensus of $4.39 billion. This miss led to nearly a 4% drop in the company’s shares in after-hours trading, highlighting difficulties in meeting market expectations (Reuters turn6news12).
On March 4, 2025, China banned imports of Illumina’s genetic sequencing machines, which make up about 7% of its total sales. Illumina responded by cutting $100 million in costs and reducing its EPS forecast to $4.50, emphasizing significant regulatory risks in an important market (Reuters turn2news13).
Illumina’s shares have dropped by almost 36% year-to-date due to trade tensions, tight funding, and ongoing market challenges, reflecting ongoing worries among investors about the company’s growth outlook and international risks (WSJ turn5news12).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

Illumina Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Illumina Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ILMN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs